Depressive Disorder Plasma

Depressive Disorder Plasma for Neuropsychiatric and Inflammation Research

Depressive Disorder Plasma is collected from IRB-consented adult donors with a clinically confirmed diagnosis of depression or major depressive disorder (MDD), and processed within one day of collection to preserve cytokines, proteins, hormones, and metabolites. Plasma is an acellular matrix, so this product supports soluble-analyte measurement rather than cell-based assays.

Depression Neurobiology and Why Plasma

Major depressive disorder is a neuropsychiatric condition. It is not an autoimmune disease, and no autoantibody or autoimmune mechanism defines it. Plasma is used to study circulating mediators that have been associated with depression and with antidepressant response.

  • Monoamine signalling (serotonin, noradrenaline, dopamine) remains the pharmacological basis of most approved antidepressants, and plasma supports drug-exposure and metabolite measurement in that context
  • Hypothalamic-pituitary-adrenal (HPA) axis regulation is a long-standing research focus; cortisol and ACTH are measurable in plasma, and altered cortisol dynamics have been reported in subsets of patients
  • A well-documented literature reports modestly elevated inflammatory markers, including CRP, IL-6 and TNF-alpha, in a subset of people with depression. This is best treated as an association rather than an established cause
  • Neurotrophic and metabolic mediators are frequently profiled, though circulating levels are sensitive to preanalytical handling and should be interpreted with matched controls
  • There is no validated diagnostic blood biomarker for depression. Plasma is appropriate for hypothesis-generating discovery, assay development, and cohort stratification, not for diagnosis
  • Unbiased proteomic and metabolomic workflows, multiplex immunoassays, and targeted ELISA all run directly on plasma

Donor Stratification Available

  • Major depressive disorder versus persistent depressive disorder
  • Treatment-naive donors versus donors currently on antidepressant therapy (SSRI, SNRI, or other class)
  • Treatment-resistant depression, defined by inadequate response to prior adequate antidepressant trials
  • Clinician-assessed severity, or standard rating-scale score where recorded
  • Presence or absence of comorbid anxiety disorder, or comorbid cardiometabolic disease
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO)
  • Plasma collected from clinically confirmed MDD donors
  • Processed within one day of collection
  • IRB-approved protocols and informed consent
  • Custom aliquot volumes available upon request
  • Anticoagulant selection available on request to match your assay

De-identified Donor Data

  • Verified MDD diagnosis
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Donor-reported medications, allergies, and comorbidities
  • Psychiatric treatment history where available
  • Additional depression-specific metadata available on request

Applications

  • Exploratory biomarker discovery in depression cohorts
  • Inflammatory marker profiling, including CRP, IL-6 and TNF-alpha
  • HPA-axis and stress-hormone measurement
  • Plasma proteomics and untargeted metabolomics
  • Immunoassay and multiplex panel development and validation
  • Antidepressant pharmacokinetic and drug-exposure studies
  • Treatment-response and treatment-resistance comparisons against matched controls
  • Reference material for neuropsychiatric assay qualification

Other Depressive Disorder Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
  • Documentation support available for regulatory review

Ordering & Customization

Depressive Disorder plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse plasma from other disease states and check live stock status, visit our human plasma page.

Protocols & Documentation

  • Plasma Isolation

    Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Plasma

Frequently Asked Questions

Showing 1–12 of 31 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Plasma cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information